VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter Cardiovascular Therapeutics (TCT) and the VEITHsymposium. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. VEITHsymposium is the leading global conference covering all aspects of vascular medicine, vascular surgery and endovascular intervention.

A new type of care for cardiac patients at St. Paul’s Hospital, Vancouver, has the potential to reduce heart imaging wait times, ease emergency department congestion and lower the number of unnecessary hospital admissions. At the center of the new approach is a dedicated cardiac computed tomography (CT) scanner, the first of its kind in Canada. The machine will be used as a component of a stand-alone Rapid Access Chest Pain Clinic that will provide earlier prevention and life-saving treatment to cardiac patients.

DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's LVivo EF artificial intelligence (AI)-based solution that generates fully automated left ventricular ejection fraction (LVEF). EF is a main indicator in assessing the global function of the left ventricle. Presently, many readers quantify EF visually or trace endocardial borders that may not be well defined, yielding high variability among results. LVivo EF aims to substantially reduce this variability by generating objective, accurate and fast AI-based EF.

New study results validate the effectiveness of the Saranas Early Bird Bleed Monitoring System to sense bleeding events during endovascular-related procedures by using sensors to detect relative changes in tissue bioimpedance. The study enrolled 60 patients from five sites who underwent an endovascular procedure and detected bleeding in more than half of patients. The results of this study were presented as late- breaking clinical research on at the Society for Cardiovascular Angiography Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and effectively reduces pressure and volume in the heart. This is the first study targeting the SVC as a therapeutic area for heart failure patients to reduce cardiac filling pressures without reducing cardiac output or systemic blood pressure. Data was presented as late-breaking clinical research at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.